Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value

• Published in: Journal of Cancer Vol. 7; no. 6; pp. 694 - 701
• Main Authors: Qiu, Miaozhen, Qiu, Huijuan, Jin, Ying, Wei, Xiaoli, Zhou, Yixin, Wang, Zixian, Wang, Deshen, Ren, Chao, Luo, Huiyan, Wang, Feng, Zhang, Dongsheng, Wang, Fenghua, Li, Yuhong, Yang, Dajun, Xu, Ruihua
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher 01.01.2016
• Subjects: Research Paper; Pathologic diagnosis; Pancreatic adenocarcinoma; SEER; Prognosis
• ISSN: 1837-9664; 1837-9664
• DOI: 10.7150/jca.14185

Even with the development of new biopsy methods, diagnosis of pancreatic cancer is sometimes without histological evidence. The aim of our study is to find out the status of pancreatic cancer patients who are diagnosed without pathologic confirm and the prognostic value of pathologic diagnosis. We identified 52,759 pancreatic adenocarcinoma patients from the Surveillance, Epidemiology, and End RESULTS (SEER) database. Logistic regression model was used to identify factors relating to no pathologic diagnosis. Multivariable Cox regression model identified potential prognostic factors. All statistical tests were two-sided. There were 6206 (11.76%) patients without pathologic diagnosis. Older age, reported from nursing/convalescent home/hospice or physician's office/private medical practitioner, early year of diagnosis, larger tumor size, pancreatic head cancer, unmarried patients, uninsured and stage I disease all contributed to no pathologic diagnosis. Median cause specific-survival for patients with and without pathologic diagnosis were 7.72 and 3.52 months, respectively. The HR for pathologic diagnosis was 0.92 (95% CI: 0.89-0.95), P<0.001. Pathologic diagnosis was an independent prognostic factor for pancreatic adenocarcinoma patients. New diagnostic methods are needed to get the pathologic diagnosis.